MetroCream Shortage: What Providers and Prescribers Need to Know in 2026

Metronidazole topical cream remains one of the most commonly prescribed treatments for papulopustular rosacea. However, clinicians are increasingly fielding calls from patients who can't find brand-name MetroCream at their pharmacy. This guide summarizes the current availability landscape, formulary considerations, substitution options, and practical strategies to support affected patients.

Current Availability Status

As of 2026, the FDA's Drug Shortage Database does not list MetroCream or generic metronidazole topical cream in an active shortage. The generic formulation (metronidazole 0.75% topical cream) is produced by multiple manufacturers and is available in the U.S. drug supply chain.

Despite this, prescribers should be aware that brand-name MetroCream is a lower-volume product. Many retail pharmacies do not stock it routinely, instead maintaining inventory of generic metronidazole cream only. Patients who present with a brand-specific prescription, especially with a "Dispense as Written" directive, may encounter real-world access challenges.

Formulary and Insurance Considerations

Generic metronidazole topical cream is generally placed at Tier 1 or Tier 2 on most commercial insurance formularies and Medicare Part D plans, with copays typically ranging from $0 to $30. Brand-name MetroCream, however, may be placed at Tier 3 or higher and frequently requires prior authorization, step therapy (requiring failure of generic first), or may not be covered at all.

In most clinical scenarios, prescribing generic metronidazole 0.75% topical cream (rather than brand MetroCream) is the most formulary-friendly approach and reduces friction at the pharmacy. Reserve brand-specific prescribing for cases where there is a clinical reason to prefer the brand formulation.

When to Consider Generic Substitution

Generic metronidazole 0.75% topical cream is FDA-approved and must meet the same bioequivalence standards as the brand. For the majority of patients with papulopustular rosacea, the generic is an appropriate and cost-effective substitute for MetroCream. Unless there is a specific reason to use the brand (e.g., sensitivity to inactive ingredients in the generic formulations), recommending or allowing generic substitution typically resolves patient access issues immediately.

Evidence-Based Alternatives When Metronidazole Is Not Accessible

For patients who cannot access any formulation of topical metronidazole, the following FDA-approved alternatives have robust clinical evidence for papulopustular rosacea:

Ivermectin 1% cream (Soolantra): Multiple Phase III trials and meta-analyses demonstrate superiority over metronidazole 0.75% cream in reducing inflammatory lesion counts and IGA scores. In one head-to-head trial of 962 patients, 86% of ivermectin patients achieved good-to-excellent improvement vs. 75% with metronidazole at 4 months. Applied once daily. Brand-only; expensive without insurance (~$400–$600 retail), but manufacturer savings programs may help.

Azelaic acid 15% gel or foam (Finacea): FDA-approved; head-to-head trials show comparable-to-superior efficacy vs. metronidazole. Works by reducing KLK5 and cathelicidin expression, inhibiting microbial survival, and modulating reactive oxygen species. Generic available. Applied twice daily. May cause more application-site burning than metronidazole.

Sub-antimicrobial doxycycline (Oracea 40 mg or generic low-dose): FDA-approved for rosacea at the 40 mg modified-release formulation. Suitable for moderate-to-severe disease or as add-on therapy. Anti-inflammatory mechanism at sub-antimicrobial doses. Generic doxycycline at sub-antimicrobial doses is commonly used off-label. Avoid in pregnancy.

Brimonidine 0.33% gel (Mirvaso) or oxymetazoline 1% cream (Rhofade): For patients whose primary complaint is erythema rather than inflammatory lesions; these vasoconstricting agents do not address papules/pustules.

37,852+ patients found their medications in stock

37K+

Find MetroCream In Stock Today →

Prior Authorization: Practical Tips for Providers

If a patient requires brand MetroCream (e.g., the generic formulation's inactive ingredients cause irritation), be prepared to document:

The specific clinical reason for brand-name prescribing over generic

Prior trial and failure of generic (if step therapy is required)

Evidence of allergy or intolerance to an ingredient specific to the generic formulation

Helping Patients Find MetroCream

Providers can direct patients to medfinder — a service that contacts pharmacies in the patient's area to check which ones can fill their prescription, then texts them the results. This eliminates the often-discouraging process of patients calling pharmacy after pharmacy on their own.

Skip the calls, skip the stress.

Find MetroCream In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Key Takeaways for Prescribers

No active FDA shortage of MetroCream or metronidazole topical cream as of 2026

Brand-name MetroCream has limited retail availability; generic is the practical standard

Generic metronidazole 0.75% cream is bioequivalent and widely stocked at major chains

Ivermectin cream (Soolantra) and azelaic acid (Finacea) are evidence-based alternatives

Consider generic prescribing to reduce insurance and access friction for patients